메뉴 건너뛰기




Volumn 20, Issue 1, 2014, Pages 18-24

A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States

(21)  Flaherty, Lawrence a   Hamid, Omid b   Linette, Gerald c   Schuchter, Lynn d   Hallmeyer, Sigrun e   Gonzalez, Rene f   Cowey, C Lance g   Pavlick, Anna h   Kudrik, Fred i   Curti, Brendan j   Lawson, David k   Chapman, Paul B l   Margolin, Kim m   Ribas, Antoni n   McDermott, David o   Flaherty, Keith p   Cranmer, Lee q   Hodi, F Stephen r   Day, Bann Mo s   Linke, Rolf s,t   more..


Author keywords

BRAF protein; brain neoplasms secondary; brain neoplasms drug therapy; clinical trial; human; humans; Melanoma drug therapy; melanoma genetics; neoplasm metastasis drug therapy; vemurafenib adverse effects; vemurafenib therapeutic use

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; B RAF KINASE; CREATINE KINASE; IPILIMUMAB; VEMURAFENIB; INDOLE DERIVATIVE; SULFONAMIDE;

EID: 84893626912     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0000000000000024     Document Type: Article
Times cited : (45)

References (12)
  • 1
    • 67449150231 scopus 로고    scopus 로고
    • Increasing burden of melanoma in the United States
    • Linos E, Swetter SM, Cockburn MG, et al. Increasing burden of melanoma in the United States. J Invest Dermatol. 2009;129:1666-1674.
    • (2009) J Invest Dermatol , vol.129 , pp. 1666-1674
    • Linos, E.1    Swetter, S.M.2    Cockburn, M.G.3
  • 2
    • 84857017872 scopus 로고    scopus 로고
    • Epidemiology of invasive cutaneous melanoma
    • MacKie RM, Hauschild A, Eggermont AMM. Epidemiology of invasive cutaneous melanoma. Ann Oncol. 2009;20(Suppl. 6):vi1-vi7.
    • (2009) Ann Oncol , vol.20 , Issue.SUPPL. 6
    • Mackie, R.M.1    Hauschild, A.2    Eggermont, A.M.M.3
  • 3
    • 84893556806 scopus 로고    scopus 로고
    • American Cancer Society. Cancer Facts and Figures, Accessed July 15 2013
    • American Cancer Society. Cancer Facts and Figures 2012. Available at: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/ document/acspc-031941.pdf. Accessed July 15, 2013.
    • (2012)
  • 4
    • 72449141073 scopus 로고    scopus 로고
    • Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline
    • Garbe C, Peris K, Hauschild A, et al. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer. 2010;46:270-283.
    • (2010) Eur J Cancer , vol.46 , pp. 270-283
    • Garbe, C.1    Peris, K.2    Hauschild, A.3
  • 5
    • 77954801079 scopus 로고    scopus 로고
    • Improved survival with ipilimumab in patients with metastatic melanoma [published correction appears in N Engl J Med 2010;363:1290]
    • Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma [published correction appears in N Engl J Med 2010;363:1290]. N Engl J Med. 2010;363:711-723.
    • (2010) N Engl J Med , vol.363 , pp. 711-723
    • Hodi, F.S.1    O'day, S.J.2    McDermott, D.F.3
  • 6
    • 84863116743 scopus 로고    scopus 로고
    • Survival in BRAF V600- mutant advanced melanoma treated with vemurafenib
    • Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600- mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366:707-714.
    • (2012) N Engl J Med , vol.366 , pp. 707-714
    • Sosman, J.A.1    Kim, K.B.2    Schuchter, L.3
  • 7
    • 79959795786 scopus 로고    scopus 로고
    • Improved survival with vemurafenib in melanoma with BRAF V600E mutation
    • BRIM-3 Study Group
    • Chapman PB, Hauschild A, Robert C, et al., BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-2516.
    • (2011) N Engl J Med , vol.364 , pp. 2507-2516
    • Chapman, P.B.1    Hauschild, A.2    Robert, C.3
  • 8
    • 84865068182 scopus 로고    scopus 로고
    • Updated overall survival results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib with dacarbazine in previously untreated patients with BRAFV600E-mutated melanoma
    • abstr 8502
    • Chapman PB, Hauschild A, Robert C, et al. Updated overall survival results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib with dacarbazine in previously untreated patients with BRAFV600E-mutated melanoma. J Clin Oncol. 2012;30(suppl; abstr 8502).
    • (2012) J Clin Oncol , vol.30 , Issue.SUPPL.
    • Chapman, P.B.1    Hauschild, A.2    Robert, C.3
  • 9
    • 84857871490 scopus 로고    scopus 로고
    • Vemurafenib sensitivity skin reaction after ipilimumab
    • Harding JJ, Pulitzer M, Chapman PB. Vemurafenib sensitivity skin reaction after ipilimumab. N Engl J Med. 2012;366:866-868.
    • (2012) N Engl J Med , vol.366 , pp. 866-868
    • Harding, J.J.1    Pulitzer, M.2    Chapman, P.B.3
  • 10
    • 84855179546 scopus 로고    scopus 로고
    • Vemurafenib for melanoma metastases to the brain
    • Rochet NM, Kottschade LA, Markovic SN. Vemurafenib for melanoma metastases to the brain. N Engl J Med. 2011;365:2439-2441.
    • (2011) N Engl J Med , vol.365 , pp. 2439-2441
    • Rochet, N.M.1    Kottschade, L.A.2    Markovic, S.N.3
  • 11
    • 84875453915 scopus 로고    scopus 로고
    • Analysis of dermatologic events in vemurafenib-treated melanoma patients
    • Lacouture ME, Duvic M, Hauschild A, et al. Analysis of dermatologic events in vemurafenib-treated melanoma patients. Oncologist. 2013;18: 314-322.
    • (2013) Oncologist , vol.18 , pp. 314-322
    • Lacouture, M.E.1    Duvic, M.2    Hauschild, A.3
  • 12
    • 84893595502 scopus 로고    scopus 로고
    • ZELBORAFi (Vemurafenib) Tablet Oral [prescribing information]. South San Francisco CA: Genentech Inc. Accessed July 15 2013
    • ZELBORAFi (Vemurafenib) Tablet, Oral [prescribing information]. South San Francisco, CA: Genentech, Inc; 2013. Available at: http://www.gene.com/ download/pdf/zelboraf-prescribing.pdf. Accessed July 15, 2013.
    • (2013)


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.